This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These therapies have broadened treatment options for patients to expand beyond the more traditional smallmolecule drug alternatives. 2 However, when dosed at the MTD, ADCs display improved efficacy over smallmolecules in oncology trials. 3D rendering of Antibody Drug Conjugate Molecules.
Now comes word of another absolutely incredible use of cryo-EM: determining with great ease and exquisite precision the structure of the smaller organic chemical compounds, or “smallmolecules,” that play such key roles in biological exploration and drug development. Also analyzed were eight less-familiar smallmolecules.
Raffaele Colombo, PhD, is Associate Director, Medicinal Chemistry at Zymeworks Inc. He has more than 14 years of experience in studying the design and synthesis of new payloads and drug-linkers for antibodies, smallmolecules, and nanoparticles. Dr Rich received a PhD in organicchemistry from the University of Alberta.
Testing Claude’s Molecule Generation Ability To test the molecule generation ability of Claude, a general-purpose LLM from Anthropic, I prompted it to generate analogs for hits from fragment screens. These fragment hits are smallmolecules with between 11 and 21 heavy atoms.
Coupling my desire to be a scientist with my keen sense of adventure, I moved to Alaska out of high school to begin my undergraduate studies in chemistry, applying myself to my STEM classes whilst also climbing mountains and chasing Northern Lights.
There, I supported AI-enabled DD efforts in their smallmolecule portfolio. After graduating, Miles went on to work as a scientist on AstraZeneca’s Research and Development graduate programme, working on projects in biocatalysis, computational organicchemistry and machine learning for drug discovery.
After completing my PhD in organicchemistry at the University of Cambridge, I went to Canada as a Leverhulme Trust postdoctoral fellow. I then moved back to the UK to work as a process chemist at GSK, designing the manufacturing routes for smallmolecule drugs. I’m a chemist by training.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content